Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure

Anitha Vijayan, Samuel C. Franklin, Terry Behrend, Marc R. Hammerman, Steven B. Miller

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


There is no pharmacological treatment to increase the glomerular filtration rate in end-stage renal disease (ESRD). The administration of 100 μg/kg of insulin-like growth factor (IGF) I twice a day to patients with ESRD increases inulin clearance. However, its effect is short-lived and IGF- I has major side effects when given this way. To assess whether the use of a lower intermittent dose of IGF-I would effect sustained improved function with tolerable side effects we performed 1) a prospective open-labeled 24- day trial in which we enrolled five patients and 2) a 31-day randomized, double-blinded, placebo-controlled trial in which we enrolled 10 patients. Patients with ESRD [creatinine clearance of <15 ml · min-1 · (1.73 m2)- 1] and scheduled to initiate renal replacement therapy received subcutaneous IGF-I, 50 μg · kg-1 · day-1, or vehicle. Treatment with IGF I resulted in significantly increased glomerular filtration rates (inulin clearances) during the 3rd and 4th wk of therapy in both prospective and double-blinded studies. Vehicle had no effect. No patient required discontinuation of drug secondary to side effects. We conclude that IGF-I effects sustained improvement of renal function (clearances comparable to those generally achieved by dialysis) in patients with ESRD and is well tolerated.

Original languageEnglish
Pages (from-to)R929-R934
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Issue number4 45-4
StatePublished - Apr 1999


  • Dialysis
  • Glomerular filtration rate
  • Growth factor
  • Middle molecules


Dive into the research topics of 'Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure'. Together they form a unique fingerprint.

Cite this